Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study pits heat, cold, and knife against lung cancer

NCT ID NCT07272356

Disease control Sponsor: Aurimas Macionis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three standard treatments for lung tumors: surgery, targeted radiation (SBRT), and minimally invasive thermal ablation (using heat or cold to destroy tumors). About 68 adults with early-stage lung cancer or limited lung metastases will be followed for two years. Researchers will measure how well each treatment controls cancer, affects breathing, and impacts quality of life, aiming to guide personalized treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Thermal ablation (microwave or cryoablation)
What this could lead to
If successful, this could help doctors choose the best treatment for each patient, balancing cancer control with preserving lung function and quality of life.
What could go wrong
This is a small, non-randomized study with only 68 participants, so results may not apply to everyone. The treatments are already standard, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Nov 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (18 years or older) * Verified systemic therapy-naive biopsy-proven NSCLC, stages from Tis to T2; or oligometastatic peripheral (≤ 5 lesions) lung disease; * All lesions are ≤3 cm in size and accessible for surgery, ablation or SBRT; * No local nodal or distant metastatic disease on diagnostic imaging; * Documented agreement on the recommended curative treatment by a multidisciplinary team, including a pulmonologist, interventional radiologist, radiation therapist, thoracic surgeon, and oncologist; * Documented patient's agreement to receive the intended therapy and to participate in this study via a signed informed consent form. Exclusion Criteria: * Central lung tumors (\<2 cm from the main bronchi or hilum); * \>5 or diffuse lung lesions, or prior local treatment to the same lesion; * Major comorbidities, physical or social limitations precluding trial participation; * Contraindications to general anesthesia, inability to temporarily withdraw antiplatelet therapy, or evidence of severe coagulopathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (non-small cell) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma Respiratory Aspiration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (non-small cell) Lung metastases from any primary

Contacts and locations

Locations

  • Lithuanian University of Health Sciences Kaunas Clinics

    Kaunas, 50161, Lithuania

More trials for these conditions

Other studies related to the condition(s) this trial covers.